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I N T R O D U C T I O N : T H E N E E D F O R C H A N G E I N
C L I N I C A L M I C R O B I O LO G Y
This is a time of rapid and fundamental change in many ¢elds
of infectious disease management. Clinical microbiology is
certainly an important part of this infectious disease manage-
ment process. But are microbiologists responding to these
changes and is clinical microbiology also changing? At ¢rst
sight, it looks as though clinical microbiology has experienced
little fundamental change over the years. As in the past, clini-
cal microbiology still predominantly relies on culturing bac-
teria for identi¢cation and susceptibility determination. As a
consequence and certainly in comparison to other ¢elds of
laboratory medicine, clinical microbiology is still labor-inten-
sive and slow. E¡orts are being made to decrease the turn-
round time of culture for identi¢cation and susceptibility test-
ing. New systems are being developed (e.g.Vitek by Biome¨r-
ieux, Walkaway by Baxter-Microscan, Phoenix by Becton-
Dickinson) that combine powerful optical systems for growth
detection in miniaturized cups and, via computerized analysis
of growth patterns, provide identi¢cation and susceptibility
testing results after hours instead of overnight incubation.
Nevertheless, compared to the classic culture-dependent
methods, the gain in terms of turn-round time of these new
culture-dependent methods will always be limited. These
new culture-dependent methods will always rely on pure bac-
terial cultures and will never be applicable directly to the sam-
ple; therefore, they will not allow same-day reporting.
Antigen and antibody detection can be applied directly to the
sample, but they are used only in speci¢c indications. Gene-
detection-based methods, in spite of the initial enthusiasm
and the huge literature on their diagnostic use, have not yet
had the dramatic impact on routine diagnostic microbiology
that many predicted.
Yet there is clearly a need for clinical microbiology to
change, particularly in view of the important challenges that
confront it.
The twomain challenges are the insu¤cient impact of clini-
cal microbiology on the management of infectious diseases
and the general drive towards more cost-e¤cientmedicine.
I M P A C T O F C L I N I C A L M I C R O B I O L O G Y O N
I N F E C T I O U S D I S E A S E M A N A G E M E N T
The impact or, more precisely, the lack of impact of clinical
microbiology on infectious disease management is most
clearly visible in the outpatient setting. Microbiological test-
ing in the outpatient setting is minimal. This is particularly
worrisome in view of the large amounts of antibiotics that are
prescribed in this setting, the mounting problems with resis-
tant pathogens in community-acquired infections and the
lack of data on many of these pathogens. The reasons behind
the limited microbiological testing are not hard to guess. The
lack of sensitivity of direct microscopic examination and of
most antigen-detection based tests and the time period of two
or more days before the microbiology culture reports come
through are powerful disincentives to perform microbiologi-
cal investigations in this setting.
But what about hospitalized patients? Surely in these
patients one would expect clinical microbiology to contribute
signi¢cantly to the treatment of infections. A 1995 report on
antibiotic prescription in Belgium in hospitalized patients
with all kinds of infections allows a deduction of the rate of
microbiological investigations [1]. It shows that in 60% of
patients with infections and who had received antibiotics, no
microbiological investigation was performed. Even more dis-
couraging are the observations reported in a few studies that
examined the use by the clinicians of the data generated by the
microbiology laboratory. These studies show that in 50% of
the cases, physicians were not aware of the reports of the
microbiological investigations they had requested themselves
[2^5]. and with alarming unanimity these studies report that,
when aware of the results, in half of the cases, physicians did
not act on the recommendations in the reports.Taken together,
these data show that the impact of clinical microbiology on
the management of infectious diseases as a whole is limited,
certainly in outpatients but also in hospitalized patients. In the
current climate of cost-e¤cient medicine, these observations
should be a source of worry to clinical microbiologists.
THE WAY FORWARD
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T H E IN T EG RA TE D L A B O R A T O R Y
This second major challenge to the current practice of diag-
nostic microbiology is the support, on ¢nancial grounds, for a
gradual dissolution of microbiology laboratories into inte-
grated laboratories [6]. In the integrated laboratory, thework is
organized around technologies and processes that are com-
mon to the di¡erent subspecialties of laboratorymedicine.The
concept of the integrated laboratory also relies heavily on the
use of automated instruments, often cross-capable, with ran-
dom access and high throughput. Technologists are cross-
trained and provide a 24 -h, 7-days out of 7 days, service. At
¢rst sight, this concept seems more suitable for clinical chem-
istry and hematology laboratories than for a microbiology
laboratory. However, antigen and antibody detection and, not
least, gene-detection based-technologies ¢t perfectly into this
concept of cross-capable common platforms. Arguments in
favor of the integrated laboratory are ¢rst and foremost the
economy of scale or the reduction of overhead per test,
coupled with high-quality, high-throughput testing and
shorter turn-round times. Of course, there are also arguments
against; one that is often heard is the threat of loss of quality
through decreased pro¢ciency of cross-trained technicians
and supervisors. The specter of large factory-like laboratories
¢lledwith rows of automata andmanaged by supervisors with
a scienti¢c and not a medical training is not very appealing to
most microbiologists.
H O W T O E N H A N C E T H E C L IN IC A L IM P A C T O F
C L IN IC A L MI C RO B IO L O G Y
How can we respond to these challenges? First, we must
increase the impact of clinical microbiology on the manage-
ment of infectious diseases.Two factors seem crucial to achieve
this goal: rapid reporting and clinically relevant reporting.
Rapid reporting does have an impact on patient manage-
ment and therefore on cost of treatment, morbidity and mor-
tality. Several studies have retrospectively investigated the
impact of rapid reporting on infectious disease management
[4,7,8]. In most studies it signi¢cantly improved the willing-
ness of physicians to follow recommendations for a change in
antibiotic therapy.Themost convincing data come from a pro-
spective study by Doern et al [9]. In this study, the impact of
rapid versus normal reporting using the same identi¢cation
and susceptibility testing systemwas prospectively examined.
The results showed conclusively that cost, morbidity and mor-
tality were signi¢cantly lower when reports were communi-
cated more rapidly. A very recent study by Barenfanger et al
[10] provides identical conclusions. It is to be expected that
methods that would allow same-day reporting, or would
require only a few hours from sampling to reporting, would
have an even greater impact on infection management. The
sooner the results are available, the more willing clinicians
appear to change their therapy or even to delay starting it. Par-
ticularly in the outpatient setting, more rapid reporting could
be an enormous advantage over the existing situation. An
example of the signi¢cant e¡ect of rapid on-site testing on
antibiotic prescription in an outpatient setting can be found in
True et al [11].
A second area for improvement is that of clinically relevant
reporting. The aim of diagnostic microbiology must be to
assist the physician in the management of infection. A ques-
tionnaire sent by Staneck to fellow physicians asking them to
de¢ne what they expected of clinical microbiology illustrates
this point [12].To most clinicians, the most important part of
the microbiology report was the advice on the antibiotic ther-
apy. Taxonomic identi¢cation was perceived as useful only
insofar as it directed antibiotic therapy. Rapid identi¢cation
that exceeded diagnostic or therapeutic necessity was said to
be of limited value.
It is probably true to assume that the attitude towards clini-
cal microbiology of most physicians lies between two
extremes. The ¢rst extreme is the attitude `I don't care what it
is, just tell me what kills it'. To these physicians, identi¢cation
is only relevant in as far as it precedes the antibiogram or is
needed to interpret the antibiogram. Sometimes it might also
be useful in understanding the infection.
At the opposite end of the spectrum is the infectious dis-
eases specialist's view. For these clinicians, identi¢cation is
relevant for interpreting the antibiogram, for establishing the
diagnosis of the disease, the origin, progression and outcome
and the clinical signi¢cance of the isolated pathogens. In this
setting, identi¢cation is also relevant for epidemiologic typing
and surveillance, or for identifying known and unknown
organisms causing infections or disease.
M O D E L S F O R C H A N G E IN D IA G N O S T IC
M I CR O B IO L O G Y
Rapid and clinically relevant reporting
A ¢rst proposal for a model for change is to make a distinction
between two settings: a therapy-oriented setting and an
added-value setting. The therapy-oriented setting includes
outpatients or non-complicated, non-compromised hospita-
lized patients. In these patients, rapid reporting is a primary
goal. But, in addition, identi¢cation as well as susceptibility
testing needs to be limited to what is relevant for therapy.
Extensive identi¢cation is not needed, and nor is extensive
susceptibility testing. In addition, microbiological testing in
this settingmust be symptom or problem oriented. For exam-
ple, testing in a case of sore throat or for cystitis must be direc-
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ted towards those pathogens that cause these infections and
relevant therapy.
In the other setting, the so-called added-value setting, we
are dealingwith recurrent, chronic and complicated infections
in compromised patients. In these patients, extensive identi¢-
cation and susceptibility testing are needed and clinically use-
ful. Here we must also strive to obtain information that is
clinically and prognostically more relevant. This added-value
reporting can be achieved by using more molecular genetic
testing. Instead of identifying phenotypes, we should start
looking for genotypes. Genotypes are clinically more relevant
than phenotypic species. Genotypes are predictive in terms of
virulence, and it is at the level of genotypes that resistance
gene detection and expression are possible. Genotypes are also
the unit of epidemiologic behavior; they are predictive of epi-
demicity. A few examples will illustrate this point. It is, for
example, awell-established fact that even among well-known
pathogens, there exist more and less pathogenic clones. For
example, of all the clones ofHaemophilus in£uenzae type b that
have been identi¢ed over the years, only three of 60 in Europe
and six of140 in theUSA are responsible for around 80% of all
invasive diseases [13]. And this, to varying degrees, is also true
for several other pathogens. It is therefore much more predic-
tive of pathogenicity and of the potential for causing infec-
tions to identify pathogens at the clonal, i.e. genetic, level.
Another genetic tool for identifying pathogens is the identi¢-
cation of genetic elements that are clearly linked to pathogeni-
city, such as pathogenicity islands. A typical example of this
can be found inHelicobacter pylori, inwhich a distinction can be
made between type I isolates, which carry the cag pathogeni-
city island and are mostly associatedwith peptic ulcer or severe
gastrointestinal disease, and the type II isolates, which are
mainly isolated from asymptomatic carriers [14].
It goes without saying that the identi¢cation of clones in
the context of nosocomial infections and the study of the epi-
demiologyof pathogens also take place at the genetic level.
As stated earlier, however, the interest of the clinicians is
not so much in the identi¢cation of pathogens but at the level
of susceptibility determination and practical advice in terms of
infection management. Genotype determination of suscept-
ibility or resistance is fairly straightforward when it comes to
identifying resistance that is based on the presence of speci¢c
resistance genes, e.g. MRSA or VRE. Detection of speci¢c
mutations in de¢ned genes, e.g. rifampin resistance in Myco-
bacterium tuberculosis, is also feasible. But what to dowhen there
are multiple genetic mechanisms that de¢ne a resistance phe-
notype, e.g. resistance to b-lactam antibiotics? Or how to
determine MIC values with genetic methods? Will this ever
be possible? Aview of what future genetic susceptibility test-
ing might look like can perhaps be found in some phenotype-
based expert systems that already exist. The Advanced Expert
System that is available on the Vitek II system of Biome¨rieux
could serve as an example. In this system, a global susceptibil-
ity pro¢le of each isolate is created that includes the determi-
nation of an MIC class for each antibiotic tested. Together
with the species identi¢cation, this is compared to an exten-
sive database that contains all documented susceptibility phe-
notypes that have been described within each species. On the
basis of matching susceptibility phenotypes, the so-called
Advanced Expert System infers the resistance mechanisms
that constitute the resistance phenotype. This resistance phe-
notype then provides the basis for therapeutic advice, includ-
ing also antibiotics that have not been tested.
A similar method can be envisaged for genotype-based sus-
ceptibility testing. By combining the identi¢cation of resis-
tance gene markers and non-resistance gene markers, a genetic
pro¢le can be created that can be compared to an extensive
database containing all documented susceptibility genotypes.
This would then allow the identi¢cation of a resistance geno-
type and the matching phenotype and provide a basis for ther-
apeutic advice regarding antibiotic treatment. At the same
time, it would provide information on the virulence potential,
pathogenicity and epidemiologic behavior of this speci¢c iso-
late.
The necessary information for the kind of database that
would be needed for this type of determination is rapidly
becoming available. Whole genome sequencing of many
pathogens is in progress and many have already been comple-
tely sequenced. At the time of writing, 20 pathogens had been
sequenced and in the public domain, and 50 were in the pro-
cess of being sequenced. and their number is increasing every
day. Our knowledge of virulence-linked genes, pathogenicity
islands and resistance genes and mechanisms is also increasing
exponentially. Coupled to this is rapid progress in the techni-
cal area, particularly in automated and rapid DNA/RNA
extraction, ampli¢cation and detection and in sequencing. A
particularly interesting development in this respect is that of
the gene chips.These tiny silicon wafers have been adapted to
allow for the analysis of many hundreds and even thousands of
hybridization events. Coupled to automated and rapid nucleic
acid extraction and ampli¢cation procedures, these would
give the analytical power to de¢ne the genotypes mentioned
earlier. The ¢rst examples of what can be accomplished with
this technology are already appearing.Two recent publications
illustrate the simultaneous identi¢cation of many di¡erent
mycobacterial species plus their resistance pro¢les through the
use of gene chips [15,16].
Point-of-care testing and the integrated laboratory
How would all of this be achieved, particularly in view of
those other challenges to diagnostic microbiology such as
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economic constraints and, more speci¢cally, the evolution
towards integrated laboratories?
How arewe to achieve rapid reporting and provide the clin-
ician with the exact level of information neededölimited
therapy-oriented testing on the one hand, and extensive
added-value testing on the other hand?
More emphasis on point-of-care testing might be part of
the answer. Limited therapy-oriented testing would best be
performed on-site. This would make the timing possible that
would convince physicians who are seeing outpatients to do
this kind of testing and delay starting treatment [11]. Of
course, this implies the development of tests that are robust
and easy to perform and interpret. It would be wrong to
assume that technological developments could never over-
come the current problems associated with point-of-care test-
ing. Genetic testing can be tailored to provide the exact level
that is needed in this setting and it would also allow for the
rapidity that would be crucial. Indeed, there are already some
examples of this kind of test in the outpatient setting.
On the other hand, there is the integrated laboratory with
its molecular diagnostics facility.The similarity of protocolsö
be they protocols for the detection of minimal residual disease
or the presence of a microorganismöand the speci¢c
demands in terms of laboratorydesign and use, e.g. preventing
contamination and technician training, make this facility an
almost natural target for integration of di¡erent subspecialties.
In addition, technology is evolving very rapidly in the ¢eld of
genetic testing, and this facility will in future be confronted
with automated cross-capable instrumentation that will pro-
vide rapid and high-throughput analysis. Rather than seeing
this development as a threat to the further existence of the
laboratory of microbiology in its current form, we should
look for the new possibilities that it will o¡er in terms of clini-
cally relevant reporting.
In conclusion, clinical microbiologists must try to do less
microbiology and more infectious disease management. As a
result, diagnostic microbiology will have more impact on
infectious disease management. A much hoped for conse-
quence would be the reduction of empirical treatment of
infectious diseases.
R E F ER E N C ES
1. PSG Hospital Anti-Infective database 1995. I. MS. #AG, 6330
Charn, Switzerland.
2. Matsen JM. Means to facilitate physician acceptance and use of
rapid test results.DiagnMicrobiol InfectDis1985; 3: 73S^8S.
3. Koontz FP. Rapid results reporting and the physician's use of
MIC's.ClinMicrobiolNewsletter1991;13: 172^4.
4. Gordon M,Trenholme GM, Raymond L et al. Clinical impact of
rapid identi¢cation and susceptibility testing of bacterial blood
culture isolates. JClinMicrobiol1989; 27: 1342^5.
5. Koontz FP. Clinical utilization of rapid antibiotic susceptibility
data: a prospective study.AdvExpMedBiol1994; 349: 27^34.
6. Robinson A,MarconM,Mortensen JE et al.Controversies a¡ect-
ing the future practice of clinical microbiology. J Clin Microbiol
1999; 37: 883^9.
7. Doern GV, Scott DR, Rashad AL. Clinical impact of rapid anti-
microbial susceptibility testing of blood culture isolates. Antimi-
crobAgentsChemother1982; 21: 1023^4.
8. Vincent P, Izard D, Lebrun Th et al. Inte¨reª t clinique des re¨sultats
rapides de bacte¨riologie au cours de l'infection nosocomiale. Presse
Med1985;14: 1697^700.
9. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of
rapid in vitro susceptibility testing and bacterial identi¢cation. J
ClinMicrobiol1994; 32: 1757^62.
10. Barenfanger J, Drake C, Kacich G. Clinical and ¢nancial bene¢ts
of rapid bacterial identi¢cation and antimicrobial susceptibility
testing. JClinMicrobiol1999; 37: 1415^18.
11. True BL, Carter BL,Driscoll CE, House JD. E¡ect of a rapid diag-
nostic method on prescribing patterns and ordering of throat cul-
tures for streptococcal pharyngitis. J Family Pract1986; 23: 215^19.
12. Staneck JL. Screening tests and r`apid' identi¢cation. Is anybody
out there listening?DiagnMicrobiol InfectDis1985; 3: 51S^7S.
13. Relman DA, Falkow S. A molecular perspective of microbial
pathogenicity. In:Mandell,Douglas and Bennett's principles and practice
of infectious diseases, 4th edn. NewYork: Elsevier Science, 1995: 19^
29.
14. Covacci A, Falkow S, Berg DE, Rappuoli R. Did the inheritance
of a pathogenicity island modify the virulence of Helicobacter
pylori?TrendsMicrobiol1997; 5: 205^8.
15. Troesch A, Nguyen H, Miyada CG et al. Mycobacterium species
identi¢cation and rifampin resistance testing with high-density
DNAprobe arrays. JClinMicrobiol1999; 37: 49^55.
16. GingerasTR, Ghandour G,Wang E et al. Simultaneous genotyp-
ing and species identi¢cation using hybridization pattern recogni-
tion analysis of generic Mycobacterium DNA arrays. Genome Res
1998; 8: 435^48.
ããð Clinical Microbiology and Infection, Volume 6 Number 8, August 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 445±448
